Literature DB >> 1384675

Characterization of the translocation breakpoint sequences of two DEK-CAN fusion genes present in t(6;9) acute myeloid leukemia and a SET-CAN fusion gene found in a case of acute undifferentiated leukemia.

M von Lindern1, D Breems, S van Baal, H Adriaansen, G Grosveld.   

Abstract

The t(6;9) associated with a subtype of acute myeloid leukemia (AML) was shown to generate a fusion between the 3' part of the CAN gene on chromosome 9 and the 5' part of the DEK gene on chromosome 6. The same part of the CAN gene appeared to be involved in a case of acute undifferentiated leukemia (AUL) as well, where it was fused to the SET gene. Genomic sequences around the translocation breakpoint were determined in two t(6;9) samples and in the case of the SET-CAN fusion. Although coexpression of myeloid markers and terminal deoxynucleotidyl transferase was shown to be one of the characteristics of t(6;9) AML, no addition of random nucleotides at the translocation breakpoint could be found. In addition, the breakpoint regions did not reveal heptamer-nonamer sequences, purine-pyrimidine tracts, a chi-octamer motif, or Alu repeats. The sequence in which the translocation breakpoints occurred was enriched in A/T. Notably, the specific introns in which clustering of breakpoints occurs in DEK and CAN both contain a LINE-I element. As LINE-I elements occur with a moderate frequency in the human genome, the presence of such an element in both breakpoint regions may be more than coincidental and may play a role in the translocation process.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384675     DOI: 10.1002/gcc.2870050309

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  35 in total

1.  The DEK nuclear autoantigen is a secreted chemotactic factor.

Authors:  Nirit Mor-Vaknin; Antonello Punturieri; Kajal Sitwala; Neil Faulkner; Maureen Legendre; Michael S Khodadoust; Ferdinand Kappes; Jeffrey H Ruth; Alisa Koch; David Glass; Lilli Petruzzelli; Barbara S Adams; David M Markovitz
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

2.  The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.

Authors:  J Martinez-Useros; I Moreno; M J Fernandez-Aceñero; M Rodriguez-Remirez; A Borrero-Palacios; A Cebrian; T Gomez Del Pulgar; L Del Puerto-Nevado; W Li; A Puime-Otin; N Perez; M S Soengas; J Garcia-Foncillas
Journal:  BMC Cancer       Date:  2018-02-06       Impact factor: 4.430

3.  MicroRNA-1292-5p inhibits cell growth, migration and invasion of gastric carcinoma by targeting DEK.

Authors:  Wentao Hui; Xiaobin Ma; Ying Zan; Lingqin Song; Shuqun Zhang; Lei Dong
Journal:  Am J Cancer Res       Date:  2018-07-01       Impact factor: 6.166

4.  Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia.

Authors:  Bing Chen; Lu Jiang; Meng-Ling Zhong; Jian-Feng Li; Ben-Shang Li; Li-Jun Peng; Yu-Ting Dai; Bo-Wen Cui; Tian-Qi Yan; Wei-Na Zhang; Xiang-Qin Weng; Yin-Yin Xie; Jing Lu; Rui-Bao Ren; Su-Ning Chen; Jian-Da Hu; De-Pei Wu; Zhu Chen; Jing-Yan Tang; Jin-Yan Huang; Jian-Qing Mi; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-26       Impact factor: 11.205

5.  TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management.

Authors:  Sounak Gupta; Sarah H Johnson; George Vasmatzis; Binu Porath; Jeannette G Rustin; Priya Rao; Brian A Costello; Bradley C Leibovich; R Houston Thompson; John C Cheville; William R Sukov
Journal:  Mod Pathol       Date:  2017-03-24       Impact factor: 7.842

6.  DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer.

Authors:  G K Fu; G Grosveld; D M Markovitz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

Review 7.  A role for intracellular and extracellular DEK in regulating hematopoiesis.

Authors:  Maegan L Capitano; Hal E Broxmeyer
Journal:  Curr Opin Hematol       Date:  2017-07       Impact factor: 3.284

8.  The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia.

Authors:  Pieter Van Vlierberghe; Martine van Grotel; Joëlle Tchinda; Charles Lee; H Berna Beverloo; Peter J van der Spek; Andrew Stubbs; Jan Cools; Kyosuke Nagata; Maarten Fornerod; Jessica Buijs-Gladdines; Martin Horstmann; Elisabeth R van Wering; Jean Soulier; Rob Pieters; Jules P P Meijerink
Journal:  Blood       Date:  2008-02-25       Impact factor: 22.113

9.  Activated glucocorticoid receptor interacts with the INHAT component Set/TAF-Ibeta and releases it from a glucocorticoid-responsive gene promoter, relieving repression: implications for the pathogenesis of glucocorticoid resistance in acute undifferentiated leukemia with Set-Can translocation.

Authors:  Takamasa Ichijo; George P Chrousos; Tomoshige Kino
Journal:  Mol Cell Endocrinol       Date:  2007-11-17       Impact factor: 4.102

10.  B-cell acute lymphoblastic leukemia associated with SET-NUP214 rearrangement: A case report and review of the literature.

Authors:  Hong-Hu Zhu; Xiao-Su Zhao; Ya-Zhen Qin; Yue-Yun Lai; Hao Jiang
Journal:  Oncol Lett       Date:  2016-02-23       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.